A first in human study investigating safety, tolerability, and pharmacokinetics of SA-001 and its metabolite Rebamipide after single oral dose of SA-001 in fasted and fed state in healthy male volunteers

Trial Profile

A first in human study investigating safety, tolerability, and pharmacokinetics of SA-001 and its metabolite Rebamipide after single oral dose of SA-001 in fasted and fed state in healthy male volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs Rebamipide (Primary) ; SA 001 (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 08 Apr 2017 New trial record
    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top